Q3 EPS Estimates for Journey Medical Reduced by Roth Capital

Journey Medical Co. (NASDAQ:DERM - Free Report) - Research analysts at Roth Capital reduced their Q3 2025 EPS estimates for shares of Journey Medical in a research note issued to investors on Monday, November 4th. Roth Capital analyst J. Wittes now anticipates that the company will earn $0.20 per share for the quarter, down from their previous estimate of $0.24. The consensus estimate for Journey Medical's current full-year earnings is ($1.04) per share. Roth Capital also issued estimates for Journey Medical's Q4 2025 earnings at $0.32 EPS and FY2025 earnings at $0.43 EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). Journey Medical had a net margin of 1.09% and a return on equity of 5.44%. The business had revenue of $14.86 million during the quarter, compared to analyst estimates of $13.81 million. During the same quarter last year, the company posted ($0.46) earnings per share.

DERM has been the subject of several other reports. Lake Street Capital initiated coverage on shares of Journey Medical in a research report on Friday, September 6th. They set a "buy" rating and a $9.00 price objective for the company. Rodman & Renshaw began coverage on shares of Journey Medical in a research note on Thursday, August 22nd. They set a "buy" rating and a $9.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Journey Medical has an average rating of "Buy" and a consensus target price of $9.38.

Journey Medical Trading Up 3.0 %

Shares of DERM traded up $0.16 during trading hours on Wednesday, hitting $5.44. 110,493 shares of the stock were exchanged, compared to its average volume of 121,964. Journey Medical has a fifty-two week low of $2.85 and a fifty-two week high of $8.11. The company has a debt-to-equity ratio of 1.75, a current ratio of 1.36 and a quick ratio of 1.08. The business has a 50-day moving average of $5.54 and a 200-day moving average of $4.96. The firm has a market capitalization of $112.75 million, a P/E ratio of -272.00 and a beta of 0.92.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DERM. Nwam LLC bought a new position in shares of Journey Medical in the first quarter valued at $41,000. Acadian Asset Management LLC lifted its stake in shares of Journey Medical by 687.5% in the first quarter. Acadian Asset Management LLC now owns 222,663 shares of the company's stock valued at $817,000 after buying an additional 194,389 shares in the last quarter. Heron Bay Capital Management bought a new position in shares of Journey Medical in the first quarter valued at $124,000. Rosalind Advisors Inc. bought a new position in shares of Journey Medical in the second quarter valued at $644,000. Finally, Cambridge Investment Research Advisors Inc. bought a new position in shares of Journey Medical in the second quarter valued at $1,664,000. 7.25% of the stock is owned by institutional investors.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.